Abstract

This study examines the strategic choices of emerging firms seeking to capitalize on revolutionary technological change. These firms exhibit rapid and significant shifts in innovation priorities and pursue substantively different strategies in their attempts to exploit a common technological discontinuity. This analysis of new U.S. biotechnology firms reveals four distinct positioning strategies that reflect differences in research and development priorities, emphases on external collaboration, and the timing of strategic choices.